{"entity":{"id":"pamiparib","kind":"drug","name":"Pamiparib","aka":["BGB-290"],"tldr":"Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.","summary":"Pamiparib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by BeiGene, in ovarian cancer. A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Pamiparib","url":"https://clinicaltrials.gov/search?intr=Pamiparib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03519230"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral PARP inhibitor","mechanism":"A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pamiparib/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"trial":[{"id":"nct03519230","kind":"trial","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","route":"/trials/nct03519230/"}]}}